Gerald E. Hanks - Concepedia

Author

Gerald E. Hanks

Also Known As

Ann Mary, G E HANKS, G E Hanks, G. E. HANKS, G. E. Hanks, G.E Hanks, G.E. Hanks, GERALD E. HANKS, Gerald E Hanks, Gerald E. Hanks

537

Publications

24.6K

Citations

H-Index

183

Concepts

All Affiliations

Fox Chase Cancer Center American College of Radiology University of Pennsylvania RTOG Foundation Massachusetts General Hospital

About

Gerald E. Hanks is an author at Fox Chase Cancer Center specializing in medicine, oncology, and radiation oncology.

Top Concepts

#	Concept	H-Index	Publications	Citations
1	Medicine	68	175	15.1K
2	Health Sciences	35	56	4K
3	Engineering	8	8	806
4	Nursing	8	8	329
5	Management	1	1	137

Gerald E. Hanks

258

Publications

23.3K

Citations

H-Index

Page 1

	Year	Citations
Defining biochemical failure following radiotherapy with or without hormonal therapy in men with clinically localized prostate cancer: Recommendations of the RTOG-ASTRO Phoenix Consensus Conference Mack Roach, Gerald E. Hanks, Howard D. Thames, International Journal of Radiation OncologyBiologyPhysics Radiation MedicineUrologyRadiation TherapyGenitourinary CancerMedicine	2006	2.7K
Phase III Trial of Long-Term Adjuvant Androgen Deprivation After Neoadjuvant Hormonal Cytoreduction and Radiotherapy in Locally Advanced Carcinoma of the Prostate: The Radiation Therapy Oncology Group Protocol 92–02 Gerald E. Hanks, Thomas F. Pajak, Arthur T. Porter, Journal of Clinical Oncology	2003	691
Ten-Year Follow-Up of Radiation Therapy Oncology Group Protocol 92-02: A Phase III Trial of the Duration of Elective Androgen Deprivation in Locally Advanced Prostate Cancer Eric M. Horwitz, Kyounghwa Bae, Gerald E. Hanks, Journal of Clinical Oncology	2008	683
Phase III trial of androgen suppression using goserelin in unfavorable-prognosis carcinoma of the prostate treated with definitive radiotherapy: report of Radiation Therapy Oncology Group Protocol 85-31. Miljenko V. Pilepich, Richard Caplan, Roger W. Byhardt, Journal of Clinical Oncology	1997	609
Radiation Therapy for Clinically Localized Prostate Cancer William U. Shipley, Howard D. Thames, Howard M. Sandler, JAMA	1999	447
Updated results of the phase III Radiation Therapy Oncology Group (RTOG) trial 85-31 evaluating the potential benefit of androgen suppression following standard radiation therapy for unfavorable prognosis carcinoma of the prostate C.A. Lawton, Kathryn Winter, Kevin Murray, International Journal of Radiation OncologyBiologyPhysics UrologyRadiation TherapyMedicineStandard Radiation TherapyProstatic Disease	2001	377
Pretreatment and treatment factors associated with improved outcome in squamous cell carcinoma of the uterine cervix: A final report of the 1973 and 1978 patterns of care studies Rachelle Lanciano, Minhee Won, Lawrence R. Coia, International Journal of Radiation OncologyBiologyPhysics Cervical Cancer ManagementGynecological SurgeryPrecancerous LesionsCervical HealthSquamous Cell Carcinoma	1991	350
The influence of treatment time on outcome for squamous cell cancer of the uterine cervix treated with radiation: A patterns-of-care study Rachelle Lanciano, Thomas F. Pajak, Karen Martz, International Journal of Radiation OncologyBiologyPhysics Squamous Cell CancerTreatment TimeCervical Cancer ManagementCervical CancerRadiation Therapy	1993	337
Preliminary report of toxicity following 3D radiation therapy for prostate cancer on 3DOG/RTOG 9406 Jeff M. Michalski, James A. Purdy, Kathryn Winter, International Journal of Radiation OncologyBiologyPhysics Radiation MedicineUrologyRadiation TherapyMedicinePreliminary Report	2000	280
The effect of dose on local control of prostate cancer Gerald E. Hanks, Karen Martz, James J. Diamond International Journal of Radiation OncologyBiologyPhysics Local ControlUrologyMedicineBrachytherapyPharmacotherapy	1988	274

Page 1